Lineage Cell Therapeutics, Inc. (LCTX) Earning

AMEX Currency in USD Disclaimer

$0.55

north_east $0.05 (9.1%)
Day's range
$0.51
Day's range
$0.56

Lineage Cell Therapeutics, Inc. Analyst EPS Estimates

Quarter Number of Estimates Low Estimate High Estimate Average Estimate
Q1 2024 1 -$0.07 -$0.02 -$0.04
Q2 2024 1 -$0.09 -$0.03 -$0.05
Q3 2024 1 -$0.08 -$0.02 -$0.04
Q4 2024 3 -$0.21 $0.06 -$0.03
Q1 2025 1 -$0.08 -$0.02 -$0.04
Q2 2025 1 -$0.08 -$0.02 -$0.04
Q3 2025 1 -$0.07 -$0.02 -$0.04
Q4 2025 1 -$0.01 -$0.00 -$0.01
Q1 2026 1 -$0.10 -$0.03 -$0.05
Q2 2026 1 -$0.10 -$0.03 -$0.05
Q3 2026 1 -$0.10 -$0.03 -$0.05
Q4 2026 1 -$0.10 -$0.03 -$0.05

Lineage Cell Therapeutics, Inc. Earnings Date And Information

Lineage Cell Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.02 earnings per share for the quarter, missing analysts' consensus estimates of $-0.01303 by $0.00697. The company had revenue of 3.78 M for the quarter and had revenue of 8.95 M for the year. Lineage Cell Therapeutics, Inc. has generated $0 earnings per share over the last year ($-0.12 diluted earnings per share) and currently has a price-to-earnings ratio of -5.24. Lineage Cell Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based on prior year's report dates.

Lineage Cell Therapeutics, Inc. Earnings History by Quarter

Date Quarter Consensus Estimate Reported EPS Beat/Miss Revenue Estimate Actual Revenue
11/14/2024 Q3 2024 -$0.01 -$0.02 -0 $1.03 M $3.78 M
08/08/2024 Q2 2024 -$0.02 -$0.03 -0.01 $943,200 $1.41 M
05/09/2024 Q1 2024 -$0.04 -$0.04 0 $1.44 M
03/07/2024 Q4 2023 -$0.07 -$0.03 0.04 $2.09 M
11/09/2023 Q3 2023 -$0.04 -$0.04 -0 $2.60 M $1.25 M
08/10/2023 Q2 2023 -$0.02 -$0.03 -0.01 $2.20 M $3.23 M
05/11/2023 Q1 2023 -$0.02 -$0.03 -0 $2.39 M
03/09/2023 Q4 2022 -$0.03 -$0.04 -0.01 $1.92 M
11/10/2022 Q3 2022 -$0.04 -$0.04 -0 $3.90 M $3.00 M
08/11/2022 Q2 2022 -$0.04 -$0.06 -0.02 $3.68 M $4.55 M
05/12/2022 Q1 2022 -$0.03 -$0.05 -0.01 $5.24 M
03/10/2022 Q4 2021 -$0.01 -$0.17 -0.16 $960,000
11/10/2021 Q3 2021 -$0.05 -$0.05 0 $510,000 $2.20 M
08/12/2021 Q2 2021 -$0.03 -$0.03 -0 $725,000 $441,000
05/13/2021 Q1 2021 -$0.04 -$0.01 0.03 $293,000
03/11/2021 Q4 2020 -$0.05 $0.01 0.06 $166,000
11/04/2020 Q3 2020 -$0.05 -$0.05 -0 $563,333 $342,000
08/06/2020 Q2 2020 -$0.04 -$0.04 -0 $557,750 $99,000
05/07/2020 Q1 2020 -$0.05 -$0.06 -0.01 $166,000
03/12/2020 Q4 2019 -$0.07 -$0.03 0.04 $832,000
 

Lineage Cell Therapeutics, Inc. Earnings: FAQ's

When is Lineage Cell Therapeutics, Inc.'s earnings date?

Lineage Cell Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 5th, 2025 based off last year's report dates.

How can I listen to Lineage Cell Therapeutics, Inc.'s earnings conference call?

The conference call for Lineage Cell Therapeutics, Inc.'s latest earnings report can be listened to online.

How can I read Lineage Cell Therapeutics, Inc.'s conference call transcript?

The conference call transcript for Lineage Cell Therapeutics, Inc.'s latest earnings report can be read online.

How much revenue does Lineage Cell Therapeutics, Inc. generate each year?

Lineage Cell Therapeutics, Inc. (:LCTX) has a recorded annual revenue of $8.95 M.

How much profit does Lineage Cell Therapeutics, Inc. generate each year?

Lineage Cell Therapeutics, Inc. (:LCTX) has a recorded net income of $8.95 M. Lineage Cell Therapeutics, Inc. has generated $-0.12 earnings per share over the last four quarters.

What is Lineage Cell Therapeutics, Inc.'s price-to-earnings ratio?

Lineage Cell Therapeutics, Inc. (:LCTX) has a price-to-earnings ratio of -5.24 and price/earnings-to-growth ratio is -0.34.

Portfolio Sync
Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED